Bone Biologics (BBLG) Total Debt (2014 - 2019)

Bone Biologics (BBLG) has reported Total Debt for 7 consecutive years, with $11.3 million the latest figure, recorded in Q4 2019.

• In Q4 2019, Total Debt changed N/A year-over-year to $11.3 million; the TTM figure through Dec 2019 stood at $11.3 million (changed N/A YoY), while the FY2019 annual figure was $11.3 million, changed N/A from the prior year.
• Total Debt rose to $11.3 million in Q4 2019 per BBLG's latest filing, from $9.0 million in the prior quarter.
• Across five years, Total Debt topped out at $20.1 million in Q3 2017 and bottomed at $3.8 million in Q1 2015.
• Historically, Total Debt has averaged $12.2 million across 5 years, with a median of $11.7 million in 2015.
• Annual changes were most pronounced in 2015 — Total Debt surged 2579.41% — and 2018, when it tumbled 55.34%.
• Bone Biologics' Total Debt stood at $12.1 million in 2015, then dropped by 27.47% to $8.8 million in 2016, then retreated by 6.09% to $8.2 million in 2017, then climbed by 9.36% to $9.0 million in 2018, then increased by 25.78% to $11.3 million in 2019.
• Business Quant data shows BBLG's Total Debt at $11.3 million in Q4 2019, $9.0 million in Q3 2018, and $8.6 million in Q2 2018.